<- Go Home

PDL BioPharma, Inc.

PDL BioPharma, Inc., together with its subsidiaries, manages various patents in the United States and internationally. The company’s patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. It offer LENSAR, which focuses on designing, developing, and marketing an femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Market Cap

$282.1M

Volume

1.3M

Cash and Equivalents

$105.4M

EBITDA

-$43.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$13.7M

Profit Margin

49.40%

52 Week High

$3.86

52 Week Low

$2.09

Dividend

N/A

Price / Book Value

0.67

Price / Earnings

-7.35

Price / Tangible Book Value

0.69

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-$46.3M

Return on Equity

7.36%

Return on Assets

-4.10

Cash and Short Term Investments

$105.4M

Debt

$13.5M

Equity

$420.0M

Revenue

$27.8M

Unlevered FCF

-$275.2M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches